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Abstract 
Software to be used in or as a medical device is subject to user requirements. However, unlike 
unregulated software, medical device software must meet both the user’s requirements and 
the requirements of the regulatory body of the region into which the software will be marketed. 
Regulatory requirements are fixed and can be planned for; unfortunately, the same is not true 
with user requirements. As many medical device software development organisations are fol-
lowing traditional sequential Software Development Life Cycles (SDLC), they are experiencing 
difficulties accommodating changes in requirements once development has begun. Agile 
methods and practices offer the ability to overcome the challenges associated with following a 
sequential SDLC. Whilst the regulatory requirements are fixed, this paper presents these re-
quirements and shows how they appear to mandate the use of a sequential SDLC. This paper 
also explains how   agile methods and practices can be successfully adopted in the develop-
ment of medical device software without hindering the process of achieving regulatory approv-
al. 
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1 Introduction 
Software is becoming an increasingly important component of medical devices, as it enables often 
complex functional changes to be implemented without having to change hardware [1]. Studies in the 
medical industry point to the fact that software is one of the most critical factors for cutting edge prod-
ucts. It is expected that, by 2015, that the research and development investment in software in this 
area will increase from 25% of the overall budget in 2002, to 33%. As the role of software in the medi-
cal device domain increases, so do the number of failures which arise due to software defects [2]. 
 
The subject of software in and as a medical device has become an important topic for the Food and 
Drug Administration (FDA). This interest began in 1985 when software in a radiation treatment therapy 
device failed as a result of software defects resulting in the administrating of a lethal overdose radia-
tion. The FDA then analysed recalls by fiscal year (FY) to determine how many were caused by soft-
ware problems. In FY 1985, for example, 20% of all neurology device recalls were attributable to soft-
ware problems, while 8% of cardiovascular problems had the same cause [3]. An analysis of medical 
device recalls by the FDA in 1996 found that software was increasingly responsible for product recalls. 
A German survey on medical device recalls indicated that software was the top cause for risks related 
to construction and design defects of medical device products. This analysis, from June 2006, showed 
that 21% of the medical device design failures were caused by software defects [2]. This was an in-
creasing trend, as the figures from November 2005 showed software was responsible for 17% of con-
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struction and design defects. This continues to be the case, and in the period: 1st January 2010 to 1st 
January 2011, the FDA recorded 80 medical device recalls and stated software as the cause [2]. This 
type of analysis, along with the results of various corporate inspections, led the FDA to conclude that 
some type of regulations was required, especially that the agency's review of medical device reporting 
(MDR) incidents and analysis of product recalls has convinced the agency that software is a factor 
contributing to practical problems within devices [3]. 
 
Since there are many types of software in use by the medical arena, the problem of the best way to 
regulate it has become an issue to the FDA. Discussions have centred on what type of software is a 
medical device, the type of regulations required for such software, and what could be inspected under 
current regulations [3]. 
 
Requirements are central to all software development projects. They are used to develop the software 
and to demonstrate that the software is performing as intended. However, in medical device software, 
requirements play an extended role. Non-regulated software must meet the requirements of the cus-
tomer or end user. Regulated software must also meet the requirements of the regulatory bodies also. 
To accompany this, as part of the regulatory requirements, a medical device software development 
organisation must be able to trace all stages of development back to the requirements. 
2 FDA Stance on Requirements 
The FDA regulations impose stringent requirements on the process by which software systems used 
in medical devices are developed. These requirements translate into various software artefacts that 
must be made available for the software to be FDA compliant [4] and, for medical device software, the 
FDA is responsible for assuring that the device utilizing the software is safe and effective [3]. 
 
FDA requires medical device manufacturers to submit their device requirements before beginning 
development. System and software requirements are taken from the FDA medical device quality sys-
tem regulation [5]. FDA regulations cover all aspects of the medical device product lifecycle, and the 
FDA requires medical device manufacturers to submit evidence of product safety and efficacy for FDA 
review and clearance before the manufacturer can market, sell, or distribute the product [6]. Thus, it is 
critical to obtain information from the FDA on the requirements applicable to the proposed device [7]. 
 
Validation compares the final product to the original specifications [8], and is closely related to the 
requirements specification. You can validate the user's requirements; this is where ambiguity reigns 
most of the time and where formal methods, through the use of specification languages, have the big-
gest strides. There is still a wide gap between what the user wants and what the developer under-
stands that the user wants. Very often this is where one of the causes of initial system failures can be 
found [9]. Software validation is the confirmation that all software requirements have been met and 
that all software requirements are traceable to the system requirements, provided that it is not possible 
to validate software without predetermined and documented software requirements [10]. There are 
two major types of validation that come into play with medical devices - design validation and process 
validation. Design validation means establishing, by objective evidence, that device specifications 
conform to the user's needs and the device's intended uses. Process validation, on the other hand, 
means establishing, by objective evidence, that a process consistently produces the desired result or 
a product meeting the predetermined specifications [11]. The FDA requires medical device manufac-
turers to submit their device specifications before beginning development [12]. Thus, validation could 
come at early stages of development if the user's requirements could be precisely defined, and which 
from them the rest of the development derived [12]. Ideally, validation work would be accomplished 
while the requirements are being written [9]. Any safety and regulatory requirements for medical de-
vices necessarily call for rigorous software development methods to ensure reliability and to protect 
public health. In addition to that, requirements and specifications based on medical practice are need-
ed to help ensure that devices will perform appropriately [6]. 
 
The regulatory bodies request that medical device software development organizations clearly 
demonstrate how they follow a software development life cycle without mandating a particular life cy-
cle [13]. In order to comply with the regulatory requirements of the medical device industry, it is neces-
sary to have clear linkages to traceability from requirements through the different stages of the soft-
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ware development and maintenance life cycles. Traceability is central to medical device software de-
velopment and essential for regulatory approval. Software traceability refers to the ability to describe 
and follow the life of a requirement in both forward and backward direction [13]. FDA for instance 
states that traceability analysis must be used to verify that a software design implements all of its 
specified requirements [14]. Thus, traceability is particularly important for medical device companies, 
as they have to demonstrate this in order to achieve FDA compliance [15]. 
2.1 Regulations and Software Development Lifecycles 
As discussed, if a medical device software manufacturer wishes to develop software, this manufactur-
er must adhere to the regulations of the region into which the device is being marketed. These regula-
tions do not mandate a Software Development Life Cycle which must be followed in order to achieve 
regulatory approval. Initial reading of these regulations and medical device software development 
standards would appear to imply that software developed for use in medical devices should be devel-
oped using a sequential plan driven development lifecycle such as the Waterfall or V-Model.  
The FDA Quality System Regulations (QSR) [16]  Subpart C – Design Controls provide information as 
to the processes which must be adhered to when developing regulatory compliant software. These 
include: 
 Design & Development Planning; (Specifications); 
 Design Output; (Coding) 
 Design Review; 
 Design Verification; (Was the Product Built Right); 
 Design Validation. (Was the Right Product Built). 
As mentioned, initial reading of the QSR would suggest completing these stages sequentially for ex-
ample in accordance with the Waterfall Model. However, the FDA Design Control Guidance for Medi-
cal Device Manufacturers [17] states: 
“Although the waterfall model is a useful tool for introducing design controls, its usefulness in practice 
is limited… for more complex devices, a concurrent engineering model is more representative of the 
design processes in use in the industry” 
The FDA General Principles of Software Validation (GPSV) [18] continues to further clarify that it does 
not mandate the use of a specific SDLC when developing regulatory compliant software:  
“this guidance does not recommend any specific life cycle model or any specific technique or method” 
Furthermore the GPSV acknowledges that activities such as Requirements Specification are likely to 
be performed iteratively and provides guidance on how these iterative development models can be 
managed. 
“Most software development models will be iterative. This is likely to result in several versions of both 
the software requirement specification and the software design specification. All approved versions 
should be archived and controlled in accordance with established configuration management proce-
dures” 
 
IEC 62304:2006 [19] is harmonised with the European Medical Device Directive (MDD) [20] and is 
approved for use by the FDA. IEC 62304:2006 is a software lifecycle model specific to the develop-
ment of medical device software. As with guidance documents, adherence to IEC 62304:2006 is not 
mandatory, however, if a manufacturer chooses not to follow it, they would need to provide a sufficient 
explanation behind not following it.  IEC 62304:2006 does not address software development lifecycle 
models; instead, it defines processes, which consist of activities that should be conducted in each 
medical device software development project [21]. As with the QSR, initial reading of IEC 62304:2006 
would appear to suggest it should be followed in accordance with a sequential lifecycle model such as 
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Waterfall Model. The publishers of IEC 62304:2006 observed that the standard appeared to mandate 
following the Waterfall Model and added the following to remove any ambiguity; 
 
“it is easiest to describe the processes in this standard in a sequence, implying a “waterfall” or “once 
through” life cycle model. However, other life cycles can also be used” 
3 Agile Methods to aid with Requirements Management 
The rapidly changing business environment in which most organizations operate is challenging tradi-
tional Requirements-Engineering (RE) approaches. Software development organizations often must 
deal with requirements that tend to evolve quickly and become obsolete even before project comple-
tion [22]. Agile methods and practices have advantages in accommodating change due to volatile 
requirements, and are most applicable to projects where requirements are ill-defined and fluid, since 
they seek to accommodate changes easily [23]. There are different agile practices and methods that 
can be used in the area of requirements management: 
 
Face-to-face communication over written specifications; effectively transferring ideas from the cus-
tomer to the development team, rather than creating extensive documentation, where simple tech-
niques (i.e. user stories) are used to define high-level requirements. Here, developers discuss re-
quirements in detail with customers before and/or during development. Thus, customers can steer the 
project in unanticipated directions, especially when their requirements change owing to changes in the 
environment or their own understanding of the software solution [22]. All agile approaches emphasize 
that talking to the customer is the best way to get information needed for development and to avoid 
misunderstandings. The CHAOS [24] report showed the critical importance of this customer involve-
ment, as it was found to be the number one reason for project success, while the lack of user involve-
ment was the main reason given for projects that ran into difficulties. A key point in all agile approach-
es is to have the customer ’accessible’ or ’on-site’. Agile methods often assume an “ideal” customer 
representative: the representative can answer all developer questions correctly, and is empowered to 
make binding decisions and able to make the right decisions [25]. This informal communication with 
customers obviates the need for time-consuming documentation and approval processes which are 
perceived unnecessary especially with evolving requirements [22]. 
 
Iterative requirements engineering; requirements here aren’t predefined, instead, they emerge during 
development. At each development cycle’s start, the customer meets with the development team to 
provide detailed information on a set of features that must be implemented. And, during this process, 
requirements are discussed at a greater level of detail. Thus, requirements are clearer and more un-
derstandable because of the immediate access to customers and their involvement in the project 
when needed [22]. 
 
Requirements prioritization; agile development implements the highest priority features early so that 
customers can realize the most business value. The feature lists are prioritized repeatedly during de-
velopment as the customer’s and the developer’s understanding of the project evolves, particularly as 
requirements are added or modified [22]. And, to keep priorities up-to-date, prioritization is repeated 
frequently during the whole development process [25]. 
 
Review meetings; at the end of each development cycle, a meeting with developers, customers, quali-
ty assurance personnel, management, and other stakeholders is held for requirements validation. 
During the meeting, the developers demonstrate the delivered features, provide progress reports to 
the customers and other stakeholders in the organization, and the customers and QA people ask 
questions and provide feedback, even though the meetings’ original purpose is to review the devel-
oped features and get feedback [22]. 
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4 Integrating Agile and Regulatory Requirements 
As discussed previously, cursory reading of medical device software standards and regulations ap-
pears to advocate utilising a plan driven SDLC that should be followed when developing regulatory 
compliant software; however, research has shown this not to be the case. Following a plan driven 
SDLC can prove successful when developing medical device software once the requirements are fully 
established up-front and there is no risk of change to them. Unfortunately, this is rarely the case and 
plan driven SDLCs have difficulties accommodating changes. Research has also shown that through 
the use of iterative development techniques, changes in requirements can be accommodated easier. 
 
While agile methods appear to solve the problems associated with following a plan driven SDLC, how 
well do agile methods align with the objectives of regulatory bodies? Agile methods appear undisci-
plined and to advocate producing none of the necessary deliverables; however, this is not the case. 
The agile manifesto states: 
 
Individuals and Interactions over processes and tools 
Working software over comprehensive documentation 
Customer collaboration over contract negotiation 
Responding to change over following a plan 
 
It can be seen that statements one and two appear to be contradictory to regulatory requirements, as 
firstly, the safety of medical device software is determined through the processes followed during the 
development of the software [26], and secondly, comprehensive documentation is a necessity when 
seeking regulatory approval. However, as highlighted in the four key principles, agile methods do not 
dictate that working software instead of comprehensive documentation, nor does it states individuals 
and interaction instead of processes and tools. The key here is the use of the term “over”. For exam-
ple, Robert Martin, a renowned agilest, clarifies this point further with regards to documentation by 
stating: 
 
“Produce no documentation unless it is of immediate business value“ 
 
In essence, with the development of medical device software, documentation is of business value; 
therefore it would still be produced while developing software in accordance with agile development 
methods. Even below the four principles on the agile manifesto [27] website, this is clarified: 
 
“While there is value in the items on the right, 
We value items on the left more” 
 
To accompany this, an additional reason cited for not being able to adopt agile methods when devel-
oping software, is that prior to development beginning, a medical device software organisation must 
register the requirements of the device. This being the case, the key benefit of adopting agile i.e. han-
dle changing requirements, become void as there can be no changes allowed. While it is the case that 
a device’s requirements must be registered with regulatory bodies prior to development, regulatory 
bodies do not require the organisation to register “nuts and bolts” requirements, rather they are con-
cerned with high level requirements. 
4.1 Aligning on Goals 
Agile software development methods are concerned with developing software using efficient tech-
niques while meeting the needs of the customer. In the case of medical device software, two custom-
ers exist, the end user and the regulatory bodies. As a result, agile methods can support regulatory 
requirements; therefore, agile methods can be supportive of regulatory requirements rather than being 
contradictory 
To accompany this, a key focus of agile development methods is the development of high quality 
software. Agile methods achieve this by increasing product development productivity and predictabil-
ity. While regulatory bodies are also concerned about the development of high quality software, they 
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are not concerned with efficiencies used during the development; however, regulatory bodies do re-
quire medical device software organisations to produce objective evidence that the software they have 
developed performs exactly as described each and every time it is used. This can be achieved 
through the predictability delivered by agile methods.   
4.2 Integration 
Previous research has shown that it is not possible to wholly follow a single agile methodology when 
developing medical device software; however, the same research revealed that combining specific 
agile practices taken from multiple agile methods and combing them with a plan driven SDLC can be 
the most advantageous to medical device software organisation. Abbott Diagnostics integrated agile 
practices with a plan driven SDLC and reported cost savings of between 35% and 50% when com-
pared to a project following a plan driven SDLC. There are a number of instances such as those that 
report the benefits of integrating agile practices; however, in each of the instances the organisations 
tailored their own SDLC with agile practices creating a proprietary SDLC. No research exists to date to 
supply a SDLC which combines agile practices with a plan driven SDLC which can be used by all 
medical device software organisation. This research will contribute to the development of such a mod-
el. 
4.2.1 Tailored Software Development Lifecycle 
When considering tailoring a SDLC, a foundation plan driven SDLC is required. For this purpose, we 
chose the V-Model for the following reasons: 
 
 Medical device software organizations typically follow the V-Model to develop medical device soft-
ware [28]. As a result, they are already familiar with the structure and phases of the V-Model and 
would be more willing to adopt a hybrid model based upon a SDLC with which they are familiar. 
 Medical device software organizations may have received regulatory approval to follow the V-
Model when developing medical device software. If these organizations move to a completely dif-
ferent SDLC, they may need to re-apply for regulatory approval for the new SDLC. This may be a 
barrier as organizations could be reluctant to undergo regulatory approval again. 
 Whilst none of the regulatory requirements or development standards mandate the use of the V-
Model, it appears to be the best fit with regulatory requirements, as it guides organizations through 
the process of producing the necessary deliverables required to achieve regulatory conformance.  
 
Once the foundation model was chosen, an analysis of this model was performed to determine where 
agile practices could be integrated to overcome the problems associated with following a plan driven 
SDLC. A number of stages remain single pass stages in the tailored model. These stages include 
“Requirements Specification”, “System Testing” and “Acceptance Tests”. These stages must remain 
single pass stages to remain in line with regulatory requirements. The remaining stages “System 
Analysis”, “Software Architecture Design”, “Software Detailed Design”, “Software Unit Implementa-
IEC 62304 5.1,5.2, 5.3 
IEC 62304 5.1 
IEC 62304 5.1 
IEC 62304 5.1,5.2, 
5.3,5.4, 5.5, 5.6,5.7  
Figure 1 IEC 62304 Mapping to Scrum Lifecycle 
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tion”, “Software Unit Test” and “Software Integration and Integration Testing” are integrated into a 
Scrum SDLC [29] (see figure 1).  
 
IEC 62304 5.1 – Software Development Planning 
IEC 62304 5.2 – Software Requirements Analysis 
IEC 62304 5.3 – Software Architectural Design 
IEC 62304 5.4 – Software Detailed Design 
IEC 62304 5.5 – Software Unit & Implementation  
IEC 62304 5.6 – Software Integration & Integration Testing 
IEC 62304 5.7 – Software System Testing 
 
A mapping study was performed in accordance with [30] which identified instances of where agile 
methods have been adopted in the development of medical device software. The mapping study iden-
tified 10 instances of where agile methods have been successfully used over the period of 2002 to 
2012. Of these the majority of the organisations involved adopted a Scrum approach with their tradi-
tional plan driven SDLC. In figure 1 the relevant processes, in accordance with IEC 62304, are 
mapped to specific stages of the Scrum Lifecycle. 
5 Conclusions 
Regulatory bodies place a large emphasis on requirements when developing medical device software. 
These requirements are used to achieve traceability and to determine if the medical device software is 
performing as intended. In an ideal scenario, prior to the development of medical device software, all 
of the stakeholders in a development team could agree and sign off on the device requirements. Once 
these requirements are agreed, a medical device software development team could adopt a 
sequential plan driven SDLC to develop the software effectively. Unfortunately, the ideal scenario 
rarely exists, and at times, changes in requirements are unavoidable, and if a development team has 
begun to develope in accordance with a plan driven SDLC, they can experience great difficulties when 
introducting a change.  
Agile methods appear to offer the silver bullet to the problem of changing requirements in 
development project. As a project is broken into iterations, a change can be introduced into the itera-
tion cycle easier than compared to a plan driven SDLC. However, while agile methods appear to be 
the silver bullet, there remains reluctance amongst medical device software organisations to adopt 
them. Research has shown that where agile practices have been adopted, they have proved 
successful. Where they have been successfuly introduced, they have been intergrated with the 
existing plan driven SDLC resulting in a scenario where the organisation can rely on the stability of 
following a plan driven SDLC whilst reaping the benefits of agile methods such as accomodatng 
changes. 
This paper maps stages of medical device software development to a Scrum development lifecycle. 
This mapping can be used by any organisation wishing to develop medical device software in 
accordance with agile methods whilst remaining compliant with regualtory controls. 
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